Start-Up Previews (10/2009)
Executive Summary
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "It’s Apples vs. Oranges in the PI3 Kinase Race," features profiles of Arno Therapeutics, Intellikine and Paloma Pharmaceuticals. Plus these Start-Ups Across Health Care: Mesynthes, Miracor Medical Systems, Silicos, Vantia and Vexim.
You may also be interested in...
Vexim SAS
Vexim's SpineJack implant for treating vertebral compression fractures looks and works much like a car jack. Once inserted into a patient's vertebra through a minimally invasive procedure, the device ratchets up to restore an anatomically correct profile. SpineJack maintains height restoration until the load bearing is transferred to bone cement. So rather than merely treating back pain, the implant also restores the anatomical shape of the vertebra.
Mesynthes Ltd.
Mesynthes Ltd.'s soft tissue regeneration and reconstruction platform, based on a proprietary extracellular matrix derived from the sheep forestomach, provides a biological template for tissue repair. Animal studies have demonstrated that the architecture of the matrix--including the vascular channels and the structural, fibrillar, and adhesive proteins, such as collagen and elastin--supports the ingress and growth of keratinocytes, fibroblasts, and mesenchymal and inflammatory cells. The extracellular matrix also releases important biological macromolecules that trigger tissue regeneration.
Miracor Medical Systems GMBH
Miracor Medical Systems aims to improve post-PCI myocardial infusion to repair the damage caused by heart attacks. The company has developed minimally invasive technology to intermittently occlude the coronary sinus to block venous outflow from the heart. The resulting rise in pressure redistributes blood in the myocardium, where Miracor believes it will regenerate damaged tissue and lead to improved outcomes for patients.